Advance on the persistent fetal vasculature

doi:10.3877/cma.j.issn.2095-2007.2022.06.006

Abstract

Abstract:

Persistent fetal vasculature (PFV) is a spectrum of disorders resulted from abnormal regression of ocular fetal vessels, which is classified into three types of anterior, posterior as well as combined. PFV presents sporadic with 95% of which is unilateral. The clinical manifestations of PFV are diverse with so many perplexed complications and is easily confused with other common eye diseases in infants and young children, made clinical diagnosis more difficult. There are no authoritative guidelines to guide treatment of PFV, and controversies exist in the treatment attitude of posterior pole lesions and the selection of surgical incisions. Moreover, clinicians do not know enough about PFV, resulting in a high rate of missed diagnosis and misdiagnosis, and the overall prognosis is poor. Therefore, the relevant literature on its embryonic origin and etiology, clinical manifestations, diagnosis and differential diagnosis, treatment, prognosis and basic research progress were reviewed.

Key words: Persistent fetal vasculature, Persistent hyperplastic primary vitreous, Hyaloid vessels, Surgery treatment

Chao Zhao, Chao Zheng, Jian Zhou. Advance on the persistent fetal vasculature[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(06): 352-356.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.06.006

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I06/352

Figures/Tables 1

References 49

[1]	Reese AB. Persistent hyperplastic primary vitreous[J]. Am J Ophthalmol, 1955, 40(3): 317－331.
[2]	Goldberg MF. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV)[J]. Am J Ophthalmol, 1997, 124(5): 587－626.
[3]	Solebo AL, Russell－Eggitt I, Cumberland P, et al. Congenital cataract associated with persistent fetal vasculature: findings from IoLunder2[J]. Eye (Lond), 2016, 30(9): 1204－1209.
[4]	Li Y, Li Z, Quan Y, et al. Macrophage recruitment in immune－privileged lens during capsule repair, necrotic fiber removal, and fibrosis[J]. iScience, 2021, 24(6): 102533.
[5]	Son AI, Sheleg M, Cooper MA, et al. Formation of persistent hyperplastic primary vitreous in ephrin－A5^－/－ mice[J]. Invest Ophthalmol Vis Sci, 2014, 55(3): 1594－1606.
[6]	Arima M, Yoshida S, Nakama T, et al. Involvement of periostin in regression of hyaloidvascular system during ocular development[J]. Invest Ophthalmol Vis Sci, 2012, 53(10): 6495－6503.
[7]	Thornton JD, Swanson DJ, Mary MN, et al. Persistent hyperplastic primary vitreous due to somatic mosaic deletion of the arf tumor suppressor[J]. Invest Ophthalmol Vis Sci, 2007, 48(2): 491－499.
[8]	Lobov IB, Rao S, Carroll TJ, et al. WNT7b mediates macro－phage－induced programmed cell death in patterning of the vasculature[J]. Nature, 2005, 437(7057): 417－421.
[9]	Wang Z, Liu CH, Huang S, et al. Assessment and characterization of hyaloid vessels in mice[J]. J Vis Exp, 2019, PMID: 31157789.
[10]	Rutland CS, Mitchell CA, Nasir M, et al. Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF－A188 from the alphaA－crystallin promoter[J]. Mol Vis, 2007, 13: 47－56.
[11]	Hahn P, Lindsten T, Tolentino M, et al. Persistent fetal ocular vasculature in mice deficient in bax and bak[J]. Arch Ophthalmol, 2005, 123(6): 797－802.
[12]	Zigler JS, Valapala M, Shang P, et al. βA3/A1－crystallin and persistent fetal vasculature (PFV) disease of the eye[J]. Biochim Biophys Acta, 2016, 1860(1): 287－298.
[13]	Maqsood H, Younus S, Fatima M, et al. Bilateral persistent hyperplastic primary vitreous: a case report and review of the literature[J]. Cureus, 2021, 13(2): e13105.
[14]	Al－Moujahed A, Callaway NF, Ludwig CA, et al. Morning glory optic nerve in Aicardi syndrome: Report of a case with fluorescein angiography[J]. Eur J Ophthalmol, 2021, 31(6): NP61－NP64.
[15]	Shastry BS. Persistent hyperplastic primary vitreous: congenital malformation of the eye[J]. Clin Exp Ophthalmol, 2009, 37(9): 884－890.
[16]	Pollard ZF. Persistent hyperplastic primary vitreous: diagnosis, treatment and results[J]. Trans Am Ophthalmol Soc, 1997, 95: 487－549.
[17]	Yeh CT, Chen KJ, Liu L, et al. Visual and anatomical outcomes with vitrectomy in posterior or combined persistent fetal vasculature in an Asian population[J]. Ophthalmic Surg Lasers Imaging Retina, 2019, 50(6): 377－384.
[18]	Kumar BR, Tripathi M, Kumari S, et al. The enigma of subnormal vision in persistent pupillary membrane[J]. Med Hypotheses, 2021, 148: 110514.
[19]	Chang M, Ancona－Lezama D, Shields CL. Vascular perfusion in persistent pupillary membrane of the iris[J]. Indian J Ophthalmol, 2019, 67(10): 1704－1705.
[20]	Lambert SR, Buckley EG, Lenhart PD, et al. Congenital fibrovascular pupillary membranes: clinical and histopathologic findings[J]. Ophthalmology, 2012, 119(3): 634－641.
[21]	Khurana S, Gupta PC, Vaiphei K, et al. A clinicopathological study of persistent fetal vasculature[J]. Indian J Ophthalmol, 2019, 67(6): 785－787.
[22]	Prakhunhungsit S, Berrocal AM. Diagnostic and Management Strategies in Patients with Persistent Fetal Vasculature: Current Insights[J]. Clin Ophthalmol, 2020, 14: 4325－4335.
[23]	Paya C, Chan H, Pechméja J, et al. Intraoperative OCT of a Mittendorf dot with persistent hyaloid artery[J]. J Fr Ophtalmol, 2016, 39(1): 109－110.
[24]	Alexandrakis G, Scott IU, Flynn HW, et al. Visual acuity outcomes with and without surgery in patients with persistent fetal vasculature[J]. Ophthalmology, 2000, 107(6): 1068－1072.
[25]	Patel M, Mukherjee D, Farsiu S, et al. Estimation of gestational age via image analysis of anterior lens capsule vascularity in preterm infants: a pilot study[J]. Front Pediatr, 2019, 7: 43.
[26]	Hu A, Pei X, Ding X, et al. Combined persistent fetal vasculature: a classification based on high－resolution B－mode ultrasound and color doppler imaging[J]. Ophthalmology, 2016, 123(1): 19－25.
[27]	赵云娥，胡曼．重视婴幼儿永存胚胎血管的诊断和治疗[J]．中华眼视光学与视觉科学杂志，2018，20(1)：7－13.
[28]	Laura DM, Staropoli PC, Patel NA, et al. Widefield fluorescein angiography in the fellow eyes of patients with presumed unilateral persistent fetal vasculature[J]. Ophthalmol Retina, 2021, 5(3): 301－307.
[29]	Huang Q, Xu Y, Zhang Q, et al. Peripheral vascular abnormalities detected by fluorescein angiography in contralateral eyes of patients with persistent fetal vasculature[J]. Ophthalmic Surg Lasers Imaging Retina, 2020, 51(9): 506－511.
[30]	Hohberger B, Knorr HLJ, Mardin CY, et al. Bilateral posterior persistent hyperplastic primary vitreous [J]. Ophthalmologe, 2018, 115(8): 680－682.
[31]	Chan LT, Gole GA, Quinn GE, et al. Pathophysiology, screening and treatment of ROP: A multi－disciplinary perspective[J]. Prog Retin Eye Res, 2018, 62: 77－119.
[32]	Tauqeer Z, Yonekawa Y. Familial exudative vitreoretinopathy: pathophysiology, diagnosis, and management[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(3): 176－182.
[33]	Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma[J]. Oncogene, 2018, 37(12): 1551－1560.
[34]	Lagrèze WA. Treatment of congenital and early childhood cataract[J]. Ophthalmologe, 2021, 118(S2): 135－144.
[35]	Aikawa Y, Baba T, Nizawa T, et al. Worsening of retinal detachment after cataract surgery in the eye with persistent fetal vasculature[J]. Case Rep Med, 2021: 6641161.
[36]	Seth NG, Kashyap H, Jurangal A, et al. Ultrasound biomicro－scopic appearance of accessory iris membrane[J]. Indian J Ophthalmol, 2019, 67(1): 122－123.
[37]	Huang YT, Lin HJ. Long term surgical outcome for persistent pupillary membranes with associated ocular abnormalities: a retrospective case series study[J]. BMC Ophthalmol, 2021, 21(1): 232.
[38]	Robb RM. Fibrous congenital iris membranes with pupillary distortion[J]. Trans Am Ophthalmol Soc, 2001, 99: 45－50.
[39]	Gavriᶊ M, Horge I, Avram E, et al. Persistent pupillary membrane or accessary iris membrane? [J]. Rom J Ophthalmol, 2015, 59(3): 184－187.
[40]	Cibis GW, Tripathi RC, Tripathi BJ. Surgical removal of congenital pupillary－iris－lens membrane[J]. Ophthalmic Surg, 1994, 25(9): 580－583.
[41]	梁天蔚，张诚玥，白大勇，等. 先天性纤维血管瞳孔膜的临床特点及治疗分析[J]. 中华眼科杂志，2018，54(11)：849－854.
[42]	Wang Q, Zhou F, Chen W, et al. A safe treatment for congenital fibrovascular pupillary membrane[J]. Eur J Ophthalmol, 2020, 30(5): 1143－1148.
[43]	Li L, Fan DB, Zhao YT, et al. Surgical treatment and visual outcomes of cataract with persistent hyperplastic primary vitreous[J]. Int J Ophthalmol, 2017, 10(3): 391－399.
[44]	Sisk RA, Berrocal AM, Feuer WJ, et al. Visual and anatomic outcomes with or without surgery in persistent fetal vasculature[J]. Ophthalmology, 2010, 117(11): 2178－2183.
[45]	Tereshchenko AV, Trifanenkova IG, Vladimirovich VM. Femto－second laser－assisted anterior and posterior capsulotomies in children with persistent hyperplastic primary vitreous[J]. J Cataract Refract Surg, 2020, 46(4): 497－502.
[46]	Bata BM, Chiu HH, Mireskandari K, et al. Long－term visual and anatomic outcomes following early surgery for persistent fetal vasculature: a single－center, 20－year review[J]. J AAPOS, 2019, 23(6): 327.
[47]	Frezzotti R, Bardelli AM, Morocutti A, et al. The pars plana approach in two cases of persistent hyperplastic primary vitreous (PHPV) [J]. Ophthalmic Paediatr Genet, 1984, 4(2): 107－110.
[48]	Khurana S, Ram J, Singh R, et al. Surgical outcomes of cataract surgery in anterior and combined persistent fetal vasculature using a novel surgical technique: a single center, prospective study[J]. Graefes Arch Clin Exp Ophthalmol, 2021, 259(1): 213－221.
[49]	Zahavi A, Weinberger D, Snir M, et al. Management of severe persistent fetal vasculature: case series and review of the literature[J]. Int Ophthalmol, 2019, 39(3): 579－587.

Please choose a citation manager

Content to export